Neuroprosthetics starts to affect health care around 2020
Grader A: hit
Grader B: hit
agrees with A, without seeing its verdict
Audit: confirmed
in the fixed audit sample (D11)
Published: hit
Grader A: hit
About 736,900 cochlear implants worldwide by Dec 2019 (183,000 in the US), plus routine deep brain stimulation. Cochlear implantation is standard care for profoundly deaf children; above 5% of the relevant population. Already here; brain-controlled prostheses alone would be partial.
Test: D37 health: share of relevant patients, providers or procedures using it by 2022 (hit >=5%; partial <5% real use by 2022 or 5% in 2023-2025; miss no real use by 2025); relevant: patients with severe-to-profound hearing loss and similar indications
Grader B: hit
The label explicitly includes cochlear implants: about 736,900 implanted worldwide by Dec 2019 (118,100 US adults, 65,000 US children), standard care for severe-to-profound deafness, with deep-brain stimulation also routine. Above 5% of the eligible pediatric population in high-income countries well before 2022. Brain-controlled prostheses alone would be partial (trials, Neuralink first implant 2024).
Test: D37 health: >=5% of relevant patients (e.g. severe-profound deafness) receive neuroprostheses by 2022 = hit (earlier counts).